Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
复制标题
基于真实临床数据的 PIVKA-II 在肝细胞癌检测中的有效性
DOI：
10.1186/s12885-017-3609-6
复制
发表时间：
2017-09-01
期刊：
影响因子：
3.8
通讯作者：
Deng G
中科院分区：
文献类型：
--
作者：
Yu R;Tan Z;Xiang X;Dan Y;Deng G
背景维生素K缺乏或拮抗剂诱导蛋白II（PIVKA-II）是肝细胞癌（HCC）的有效特异性生物标志物。一些研究人员已经证明，PIVKA-II的水平反映了HCC的发生和进展。然而，PIVKA-II的有效性的基础上，现实世界的临床data.MethodsA的14,861样本，在西南医院在超过2年的时间进行了测试，几乎没有研究。其中，4073份样本为PIVKA-II阳性。最后，共有2070例至少接受过两次影像学检查的患者入选本研究。AFP和PIVKA-II的水平测定化学发光酶免疫分析法（CLEIA）和荧光微粒子免疫分析法（CMIA），respectively.ResultsA共检测1016例HCC患者的PIVKA-II在现实世界中的应用。原发性肝癌占88.7%，晚期肝癌占61.3%。晚期组PIVKA-II水平（4650.0 mAU/ml、667.0-33,438.0 mAU/ml）明显高于早期组（104.5 mAU/ml、61.0-348.8 mAU/ml;P< 0.001）。复发组和残留组PIVKA-II水平明显高于恢复组（P< 0.001）。共1054例PIVKA-II阳性患者为非HCC病例。其中肝硬化最多（46.3%），其次为肝炎（20.6%）和良性结节（15.3%）。高水平的PIVKA-II在高危患者是一个指标，HCC的发展，在两年的时间。ConclusionsOur数据表明，PIVKA-II有效地提高了肝癌的检出率是一个有效的补充AFP和影像学检查在肝癌监测。
BackgroundProtein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied.MethodsA total of 14,861 samples were tested in Southwest Hospital in over 2 years’ time. Among them, 4073 samples were PIVKA-II positive. Finally, a total of 2070 patients with at least two image examinations were enrolled in this study. Levels of AFP and PIVKA-II were measured by chemiluminescence enzyme immunoassay (CLEIA) and chemiluminescent microparticle Immunoassay (CMIA), respectively.ResultsA total of 1016 patients with HCC were detected by PIVKA-II in a real-world application. In all these cases, 88.7% cases primarily occurred and patients with advanced HCC covered 61.3%. Levels of PIVKA-II were significantly higher in advanced group (4650.0 mAU/ml, 667.0–33,438.0 mAU/ml) than early-stage group (104.5 mAU/ml, 61.0–348.8 mAU/ml;P< 0.001). Levels of PIVKA-II elevated significantly in recurrence and residual group than recovery group (P< 0.001). A total of 1054 PIVKA-II positive patients were non-HCC cases. Among them, cirrhosis took the largest part (46.3%), followed by hepatitis (20.6%) and benign nodules (15.3%). High-levels of PIVKA-II in at-risk patients is an indicator of HCC development in two-year time.ConclusionsOur data showed that PIVKA-II effectively increases the detection rate of HCC was a valid complement to AFP and image examination in HCC surveillance.
登录
查看更多内容
影响因子：
29.4
作者：
El-Serag HB
通讯作者：
El-Serag HB
影响因子：
8
作者：
Kim, Seok-Hwan;Moon, Deok-Bog;Lee, Sung-Gyu
通讯作者：
Lee, Sung-Gyu
影响因子：
13.5
作者：
Marrero, JA;Su, GL;Lok, AS
通讯作者：
Lok, AS
影响因子：
25.7
作者：
Pote, Nicolas;Cauchy, Franois;Paradis, Valerie
通讯作者：
Paradis, Valerie
影响因子：
8.4
作者：
通讯作者：
--